- Home
- MESO vs EOS Comparison
MESO vs EOS Comparison
Compare MESO & EOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MESO
- EOS
- Stock Information
- Founded
- MESO 2004
- EOS 2005
- Country
- MESO Australia
- EOS United States
- Employees
- MESO N/A
- EOS N/A
- Industry
- MESO Biotechnology: Biological Products (No Diagnostic Substances)
- EOS Trusts Except Educational Religious and Charitable
- Sector
- MESO Health Care
- EOS Finance
- Exchange
- MESO Nasdaq
- EOS Nasdaq
- Market Cap
- MESO 1.3B
- EOS 1.3B
- IPO Year
- MESO N/A
- EOS N/A
- Fundamental
- Price
- MESO $14.82
- EOS $24.46
- Analyst Decision
- MESO Buy
- EOS
- Analyst Count
- MESO 3
- EOS 0
- Target Price
- MESO $18.00
- EOS N/A
- AVG Volume (30 Days)
- MESO 230.7K
- EOS 84.1K
- Earning Date
- MESO 08-28-2025
- EOS 01-01-0001
- Dividend Yield
- MESO N/A
- EOS 6.80%
- EPS Growth
- MESO N/A
- EOS N/A
- EPS
- MESO N/A
- EOS N/A
- Revenue
- MESO $17,198,000.00
- EOS N/A
- Revenue This Year
- MESO $293.59
- EOS N/A
- Revenue Next Year
- MESO $218.64
- EOS N/A
- P/E Ratio
- MESO N/A
- EOS N/A
- Revenue Growth
- MESO 191.39
- EOS N/A
- 52 Week Low
- MESO $6.00
- EOS $15.62
- 52 Week High
- MESO $22.00
- EOS $20.63
- Technical
- Relative Strength Index (RSI)
- MESO 50.33
- EOS 63.63
- Support Level
- MESO $12.66
- EOS $23.58
- Resistance Level
- MESO $15.67
- EOS $24.49
- Average True Range (ATR)
- MESO 0.45
- EOS 0.21
- MACD
- MESO -0.00
- EOS 0.06
- Stochastic Oscillator
- MESO 59.83
- EOS 96.70
About MESO Mesoblast Limited
Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.
About EOS Eaton Vance Enhance Equity Income Fund II
Eaton Vance Enhanced Equity Income Fund II is a diversified, closed-end management investment company. The fund's primary investment objective is to provide current income, with a secondary objective of capital appreciation. Under normal market conditions, the Fund invests at least 80% of its total assets in common stocks. It invests in a portfolio of large and mid-cap securities in sectors such as Information Technology, Consumer Discretionary, Communication Services, Healthcare, Industrials, Consumer Staples, Financials, Materials, and Energy.